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can present with inﬂammatory bowel disease (monogenic
IBD). Patients with these disorders often develop symptoms
during infancy or early childhood, along with endoscopic or
histological features of Crohn’s disease, ulcerative colitis, or
IBD unclassiﬁed. Defects in interleukin-10 signaling have a
Mendelian inheritance patternwith complete penetrance of
intestinal inﬂammation. Several genetic defects that disturb
intestinal epithelial barrier function or affect innate and
adaptive immune function have incomplete penetrance of
the IBD-like phenotype. Several of these monogenic condi-
tions do not respond to conventional therapy and are asso-
ciated with high morbidity and mortality. Due to the broad
spectrum of these extremely rare diseases, a correct diag-
nosis is frequently a challenge and often delayed. In many
cases, these diseases cannot be categorized based on stan-
dard histological and immunologic features of IBD. Genetic
analysis is required to identify the cause of the disorder and
offer the patient appropriate treatment options, which
include medical therapy, surgery, or allogeneic hematopoi-
etic stem cell transplantation. In addition, diagnosis based
on genetic analysis can lead to genetic counseling for family
members of patients. We describe key intestinal, extra-
intestinal, and laboratory features of 50 genetic variants
associated with IBD-like intestinal inﬂammation. In addi-
tion,weprovide approaches for identifying patients likely to
have these disorders. We also discuss classic approaches to
identify these variants in patients, starting with phenotypic
and functional assessments that lead to analysis of candi-
date genes. As a complementary approach, we discuss par-
allel genetic screening using next-generation sequencing
followed by functional conﬁrmation of genetic defects.whole-exome sequencing.
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Next-Generation Sequencing; Whole Exome Sequencing.nﬂammatory bowel diseases (IBDs) are a diverse groupIof complex and multifactorial disorders. The most
common subtypes are Crohn’s disease (CD) and ulcerative
colitis (UC).1,2 There is increasing evidence that IBD arises in
genetically susceptible people, who develop a chronic and
relapsing inﬂammatory intestinal immune response toward
the intestinal microbiota. Disease development and pro-
gression are clearly inﬂuenced by environmental factors,
which have contributed to the rapid global increase in the
incidence of IBD in recent decades.3
Developmental, Genetic, and Biological
Differences Among Age Groups
IBD location, progression, and response to therapy have
age-dependent characteristics.4–10 The onset of intestinal
inﬂammation in children can affect their development and
growth. Age of onset can also provide information about the
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patients with defects in interleukin (IL)-10 signaling have a
particularly early onset of IBD, within the ﬁrst few months of
life. Our increasing understanding of age-speciﬁc character-
istics has led to changes in the classiﬁcation of pediatric IBD.
Based on disease characteristics, several age subgroups have
been proposed that correspond largely to the generally
accepted age stages deﬁned by National Institute of Child
Health and Human Development pediatric terminology.11
Fivemajor subgroups of pediatric IBD can be summarized
according to age (Table 1). The Montreal classiﬁcation12
originally deﬁned patients with age of onset younger than
17 years as a distinct group of patients with pediatric-onset
IBD (A1). The Pediatric Paris modiﬁcation13 of the Mon-
treal classiﬁcation12 later deﬁned the pediatric-onset group
of IBD as A1 but subdivided those with a diagnosis before 10
years of age as subgroup A1a and those with a diagnosis
between 10 and <17 years of age as subgroup A1b.13 This
reclassiﬁcation was based on several ﬁndings indicating that
children with a diagnosis of IBD before 10 years of age
develop a somewhat different disease phenotype compared
with adolescents or adults. Particular differences that sup-
ported the modiﬁcation were paucity of ileal inﬂammation
and predominance of pancolonic inﬂammation as well as a
low rate of anti–Saccharomyces cerevisiae antibodies in A1a
patients with CD, with an increased risk of surgery (colec-
tomy) and biological therapy in A1a patients with UC.13
In this review, we refer to the A1a group as having early-
onset IBD (EOIBD). Very early onset IBD (VEOIBD), the
subject of this review, represents children with a diagnosis
before 6 years of age.14 This age classiﬁcation includes
neonatal, infantile, toddler, and early childhood groups.
Proposing an age group between infantile IBD and A1a
EOIBD makes sense when taking account that the age of
onset is often older than 2 years in multiple relevant sub-
groups of patients with monogenic IBD (such as those with
XIAP deﬁciency, chronic granulomatous disease [CGD], or
other neutrophil defects). On the other hand, from the age of
7 years, there is a substantial rise in the frequency of pa-
tients with a diagnosis of conventional polygenic IBD,
particularly CD.6,15 This leads to a relative enrichment of
monogenic IBD in those with age of onset younger than 6
years. Approximately one-ﬁfth of children with IBD younger
than 6 years of age and one-third of children with IBD
younger than 3 years of age are categorized as having IBD
unclassiﬁed (or indeterminate colitis),16 reﬂecting the lack
of a reﬁned phenotyping tool to categorize relevantTable 1.Subgroups of Pediatric IBD According to Age
Group Classiﬁcation Age range (y)
Pediatric-onset IBD Montreal A1 Younger than 17
EOIBD Paris A1a Younger than 10
VEOIBD Younger than 6
Infantile (and toddler)
onset IBD
Younger than 2
Neonatal IBD First 28 days of agesubgroups of patients with VEOIBD and a potential bias due
to incomplete diagnostic workup in very young children.15
The enrichment of monogenic defects in EOIBD and
VEOIBD becomes apparent when relating the approximately
1% of patients with IBD younger than 6 years of age and
<0.2% younger than 1 year of age to reports that the ma-
jority of monogenic disorders can present at younger than 6
years of age and even younger than 1 year of age (Figure 1).
Although it is generally accepted that many patients with
VEOIBD have low response rates to conventional anti-
inﬂammatory and immunomodulatory therapy, there is a
paucity of well-designed studies to support this hypothesis.
Infantile (and toddler) onset of IBD was highlighted in the
Pediatric Paris classiﬁcation because of higher rates of
affected ﬁrst-degree family relatives, indicating an increased
genetic component, severe disease course, and high rate of
resistance to immunosuppressive treatment.13 Features of
autoimmunity with dominant lymphoid cell inﬁltration are
frequently found in infants and toddlers.17 Such patients are
likely to have pancolitis; subgroups of patients develop
severely ulcerating perianal disease, and there is a high rate
of resistance to conventional therapy, a high rate of ﬁrst-
degree relatives with IBD, and increased lethality.4–8
Recent guidelines and consensus approaches on the diag-
nosis and management of IBD18,19 highlight that children
with infantile onset of IBD have a particular high risk of an
underlying primary immunodeﬁciency. An extreme early
subgroup, neonatal IBD, has been described with manifes-
tations during the ﬁrst 27 days of life.4,5,8
Guidelines on the diagnosis and classiﬁcation of IBD in
pediatric patients13,18–21 have addressed the need to
recognize monogenic disorders and immunodeﬁciencies in
particular, because these require a different treatment
strategy than conventional IBD. Current guidelines do not,
however, cover the spectrum of these rare subgroups of
monogenic IBD. The identiﬁcation of an underlying genetic
defect is indeed challenging, owing to the orphan nature of
these diseases, the wide phenotypic spectrum of disorders,
and the limited information available on most genetic de-
fects. This review and practice guide provides a compre-
hensive summary of the monogenic causes of IBD-like
intestinal inﬂammation and a conceptual framework for the
diagnostic evaluation of patients with suspected monogenic
IBD. We categorize known genetic defects into functional
subgroups and discuss key intestinal and extraintestinal
ﬁndings. Based on the enrichment of known causative mu-
tations as well as extreme phenotypes in very young chil-
dren, we have focused on a practical approach to detect
monogenic disorders in patients with VEOIBD and infantile
IBD in particular. Because there is only modest biological
evidence to support age-speciﬁc categorization of IBD above
infantile IBD and within the EOIBD subgroup, we also
discuss disease- and gene-speciﬁc ages of onset of intestinal
inﬂammation (Figure 1).Epidemiology of Pediatric IBD
Approximately 20% to 25% of patients with IBD develop
intestinal inﬂammation during childhood and adolescence.
Figure 1. Age of onset of
IBD-like symptoms in pa-
tients with monogenic dis-
eases. Multiple genetic
defects are summarized
in the group of atypical
SCID, Hoyeraal–Hrei-
darsson syndrome, CGD,
and Hermansky–Pudlak
syndrome. By comparison,
an unselected IBD popula-
tion is presented (Oxford
IBD cohort study; pediatric
and adult referral-based
IBD cohort, n ¼ 1605 pa-
tients comprising CD,
UC, and IBD unclassiﬁed
[IBDU]). Symbols represent
individual patients. Bars
represent the age range of
caseseries if individualdata
were not available. The age
ranges of infantile IBD,
VEOIBD, EOIBD, and Mon-
treal/Paris classiﬁcation
A1a, A1b, A2, and A3 are
shown for reference. Age of
onset data refer to refer-
ences provided in Table 2.
Additional references for
disease subgroups are
provided in Supplementary
Information for Figure 1.
992 Uhlig et al Gastroenterology Vol. 147, No. 5
REVIEW
S
AND
PERSPECTIVESIBD in children younger than 1 year of age has been re-
ported in approximately 1% and VEOIBD in approximately
15% of pediatric patients with IBD.6 VEOIBD has an esti-
mated incidence of 4.37 per 100,000 children and a prev-
alence of 14 per 100,000 children.22 The incidence of
pediatric IBD is increasing.22,23 Some studies have reported
that the incidence of IBD is increasing particularly rapidly in
young children,24,25 although not all studies have conﬁrmed
this observation.9Polygenic and Monogenic Forms of IBD
Twin studies have provided the best evidence for a ge-
netic predisposition to IBD, which is stronger for CD than
UC. Conventional IBD is a group of polygenic disorders in
which hundred(s) of susceptibility loci contribute to the
overall risk of disease. Meta-analyses of (genome-wide) as-
sociation studies of adolescent- and adult-onset IBD iden-
tiﬁed 163 IBD-associated genetic loci encompassing
approximately 300 potential candidate genes. However, it is
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contribute only a small percentage of the expected herita-
bility in IBD.26 This suggests that IBD, including CD and UC,
can be regarded as a classic polygenic disorder. Findings
from initial genome-wide pediatric association studies
focused on adolescents and conﬁrm a polygenic model.27,28
There are no well-powered genome-wide association
studies of patients with EOIBD or VEOIBD.
Although most cases of IBD are caused by a polygenic
contribution toward genetic susceptibility, there is a diverse
spectrum of rare genetic disorders that produce IBD-like
intestinal inﬂammation.29 The genetic variants that cause
these disorders have a large effect on gene function. How-
ever, these variants are so rare in allele frequency (many
private mutations) that those genetic signals are not
detected in genome-wide association studies of patients
with IBD. With recent advances in genetic mapping and
sequencing techniques and increasing awareness of the
importance of those “orphan” disorders, approximately 50
genetic disorders have been identiﬁed and associated with
IBD-like immunopathology (for a partial summary, see
Uhlig29). For simplicity, we refer to these disorders in the
following text as monogenic IBD, even if there is a spectrum
of penetrance of the IBD phenotype. We will compare those
monogenic forms of IBD with polygenic conventional IBD.
All data suggest that the fraction of monogenic disorders
with IBD-like presentation among all patients with IBD
correlates inversely with the age of onset. Despite a growing
genotype spectrum, monogenic disorders still account for
only a fraction of VEOIBD cases. The true fraction is un-
known. In a study of 66 patients who developed IBD at ages
younger than 5 years, 5 patients were found to carry mu-
tations in IL10RA, 8 in IL10RB, and 3 in IL10.30 All patients
developed symptoms within the ﬁrst 3 months of life.30 A
recent study detected 4 patients with presumed pathogenic
XIAP mutations in a group of 275 patients with pediatric
IBD (A1a/A1b Paris classiﬁcation) and 1047 patients with
adult-onset CD (A2 and A3 Montreal classiﬁcation).31
Because all patients with XIAP variants were infantile to
adolescent male patients with CD, this could suggest an
approximate prevalence of 4% among young male patients
with IBD. However, studies like these focus on speciﬁc genes
and may have strong selection bias toward an expected
clinical subphenotype. They might therefore overestimate
the frequency of speciﬁc variants. Analysis of large, multi-
center, population-based cohorts is needed to determine the
proportion of cases of VEOIBD caused by single gene defects
and to estimate penetrance.
Monogenic defects have been found to alter intestinal
immune homeostasis via several mechanisms (Table 2).
These include disruption of the epithelial barrier and the
epithelial response as well as reduced clearance of bacteria
by neutrophil granulocytes and other phagocytes. Other
single-gene defects induce hyperinﬂammation or auto-
inﬂammation or disrupt T- and B-cell selection and activa-
tion. Hyperactivation of the immune response can result
from defects in immune inhibitory mechanisms, such as
defects in IL-10 signaling or dysfunctional regulatory T-cell
activity.Epithelial Barrier and Response Defects
Genetic disorders that affect intestinal epithelial barrier
function include dystrophic epidermolysis bullosa,32 Kindler
syndrome,32 familial diarrhea caused by dominant acti-
vating mutations in guanylate cyclase C,33 X-linked ecto-
dermal dysplasia and immunodeﬁciency,34 and ADAM17
deﬁciency.35
X-linked ectodermal dysplasia and immunodeﬁciency,
caused by hypomorphic mutations in IKBKG (encodes nu-
clear factor kB essential modulator protein [NEMO])34 and
ADAM17 deﬁciency35 cause epithelial and immune
dysfunction. Recently, TTC7A deﬁciency was described in
patients with multiple intestinal atresia, with and without
severe combined immunodeﬁciency (SCID) immunodeﬁ-
ciency.36,37 Hypomorphic mutations in TTC7A have been
found to cause VEOIBD without intestinal stricturing or
severe immunodeﬁciency, most likely due to a defect in
epithelial signaling.38
Dysfunction of Neutrophil Granulocytes
Variants in genes that affect neutrophil granulocytes
(and other phagocytes) predispose people to IBD-like in-
testinal inﬂammation. Chronic granulomatous disease is
characterized by genetic defects in components of the
phagocyte reduced nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase (phox) complex. Genetic mu-
tations in all 5 components of the phagocyte NADPH oxidase
(phox)—gp91-phox (CYBB), p22-phox (CYBA), p47-phox
(NCF1), p67-phox (NCF2), and p40-phox (NCF4)—are
associated with immunodeﬁciency and can cause IBD-like
intestinal inﬂammation.
As high as 40% of patients with CGD develop CD-like
intestinal inﬂammation.39–41 Multiple granulomas and the
presence of pigmented macrophages can indicate the group
of defects histologically. Missense variants in NCF2 that
affect RAC2 binding sites have recently been reported in
patients with VEOIBD.42 Recently, several heterozygous
functional hypomorphic variants in multiple components of
the NOX2 NADPH oxidase complex were detected in pa-
tients with VEOIBD that do not cause CGD-like immunode-
ﬁciency but have a moderate effect on reactive oxygen
species production and confer susceptibility to VEOIBD.43
Tumor necrosis factor a inhibitors can resolve intestinal
inﬂammation in patients with CGD but could increase the
risk of severe infections in patients with CGD.44 Allogeneic
hematopoietic stem cell transplantation (HSCT) can cure
CGD and resolve intestinal inﬂammation.44–46 Monocytes
produce high levels of IL-1 in patients with CGD, and an IL-1
receptor antagonist (anakinra) has been used to treat
noninfectious colitis in those patients.47
In addition to CGD, a number of other neutrophil
defects are associated with intestinal inﬂammation. Defects
in glucose-6-phosphate translocase (SLC37A4)48,49 and
glucose-6-phosphatase catalytic subunit 3 (G6PC3)50 are
associated with congenital neutropenia (and other distinc-
tive features) but also predispose people to IBD. Leukocyte
adhesion deﬁciency type 1 is caused by mutations in the
gene encoding CD18 (ITGB2) and is associated with
Table 2.Genetic Defects and Phenotype of Monogenic IBD
Group Syndrome/disorder Gene Inheritance
Intestinal ﬁndings Extraintestinal ﬁndings
References
CD-
like Granuloma
UC-
like
Epithelial
defect
(apoptosis)
Disease
location
(1–5)
Perianal
ﬁstula/
abscess
Penetrating
ﬁstulas Strictures
S
les s
Autoimmunity,
inﬂammation
HLH/
MAS Neoplasia
1 Epithelial barrier Dystrophic bullosa COL7A1 AR þ 3 þ eb 32 (A. Martineza)
2 Kindler syndrome FERMT1 AR þ þ 5 þ eb 32, 149
(A. Martineza)
3 X-linked ectodermal
immunodeﬁciency
IKBKG X þ þ 3 þ A, Vasc 34, 150, 151
4 TTC7A deﬁciency TTC7A AR þ 3 þ 38
5 ADAM17 deﬁciency ADAM17 AR (þ) þ 3 n, 35
6 Familial diarrhea GUCY2C AD þ 3 þ 33 (A. Janeckea)
7 Phagocyte defects CGD CYBB X þ þ 1, 3 þ e 39
8 CGD CYBA AR þ þ 3 þ e 41
9 CGD NCF1 AR þ þ 1, 3 þ e 39
10 CGD NCF2 AR þ þ 1, 3 þ e 39
11 CGD NCF4 AR þ þ 1, 3 e 40
12 Glycogen storage disease
type Ib
SLC37A4 AR þ þ 1, 3 þ þ f 48, 49, 53
13 Congenital neutropenia G6PC3 AR þ 1, 3 þ ? (þ) f 50, 138, 152
14 Leukocyte adhesion
deﬁciency 1
ITGB2 AR þ 1, 3 þ þ f 51, 52
15 Hyperinﬂammatory
and
Mevalonate kinase
deﬁciency
MVK AR 3 þ þ A, SJ þ 54, 55, 71
16 autoinﬂammatory
disorders
Phospholipase C-g2
defects
PLCG2 AD þ 3 (eb e A, NSIP 56
17 Familial Mediterranean
fever
MEFV AR þ 5 þ S 57–59
18 Familial hemophagocytic
lymphohistiocytosis
type 5
STXBP2 AR 3 þ 69
19 X-linked
lymphoproliferative
syndrome 2 (XLP2)
XIAP X þ þ 3 þ þ (þ) þ ? þ 31, 66–68, 72,
73, 127
20 X-linked
lymphoproliferative
syndrome 1 (XLP1)
SH2D1A X 3 þ þ 65
21 Hermansky–Pudlak 1 HPS1 AR þ þ 3 þ (þ) þ 60–63
22 Hermansky–Pudlak 4 HPS4 AR þ þ 3 þ (þ) þ 60, 62, 153
23 Hermansky–Pudlak 6 HPS6 AR 3 þ 64
24 T- and B-cell defects CVID 1 ICOS AR 5 p A 86
25 CVID 8 LRBA AR þ 3 EN AIHA 87–89
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Table 2.Continued
Group Syndrome/disorder Gene Inheritance
Intestinal ﬁndings Extraintestinal ﬁndings
References
CD-
like Granuloma
UC-
like
Epithelial
defect
(apoptosis)
Disease
location
(1–5)
Perianal
ﬁstula/
abscess
Penetrating
ﬁstulas Strictures
Skin
lesions
Autoimmunity,
inﬂammation
HLH/
MAS Neoplasia
26 IL-21 deﬁciency (CVID-like) IL21 AR þ þ 90
27 Agammaglobulinemia BTK X þ 5 AIHA 75, 76
28 Agammaglobulinemia PIK3R1 AR 5 EN þ 77
29 Hyper IgM syndrome CD40LG X 1, 5 þ AIHA 78
30 Hyper IgM syndrome AICDA AR þ 1, 3 AIHA 79
31 WAS WAS X þ 5 e AIHA, A 80
32 Omenn syndrome DCLRE1C AR þ 1, 3 81
33 SCID ZAP70 AR þ 5 e 154
34 SCID/hyper IgM syndrome RAG2 AR 5 þ AIHA 82, 155
35 SCID IL2RG X 3 156, 157
36 SCID LIG4 AR No further information þ AN 82
37 SCID ADA AR No further information þ AIHA 82
38 SCID CD3g AR þ 5 þ þ 95
39 Hoyeraal–Hreidarsson S. DKC1 X (þ) 1, 3 þ þ, n, h þ 99–101
40 Hoyeraal–Hreidarsson S. RTEL1 AR þ 5 þ þ, n, h þ 97, 98
41 Hyper IgE syndrome DOCK8 AR þ 1, 5 e PSC 158
42 Immunoregulation IPEX FOXP3 X 3 e, p AIHA, HT,
T1D.
111, 112
43 IPEX-like IL2RA AR 2 e AIHA, HT,
T1D.
114
44 IPEX-like STAT1 AD 2 116
45 IL-10 signaling defects IL10RA AR þ (þ) 3 þ þ f, e A þ 30, 102–105, 107
46 IL-10 signaling defects IL10RB AR þ (þ) 3 þ þ f A, AIH þ 30, 102–105, 107
47 IL-10 signaling defects IL10 AR þ 3 þ þ 30, 102, 104,
105, 107
48 Others MASP deﬁciency MASP2 AR þ þ A 159
49 Trichohepatoenteric S. SKIV2L AR 3 h, þ 117, 160
50 Trichohepatoenteric S. TTC37 AR 3 h, þ 117
NOTE. Genetic defects are grouped according to functional subgroups. Gene names refer to HUGO gene nomenclature. CD-like and UC-like were marked only when
patient characteristics in the original reports were described as typical CD or UC pathologies. Unclassiﬁed or indeterminate colitis is the not speciﬁed default option.
Disease location is classiﬁed as follows: 1, mouth; 2, enteropathy; 3, enterocolitis; 4, isolated ileitis; 5, colitis; 6, perianal disease. Epithelial defects refer in particular to
ﬁnding of epithelial lining nonadherent at the basal membrane or increased epithelial apoptosis and epithelial tufting. Key laboratory ﬁndings are provided in Supplementary
Table 1, and examples of additional defects of possible or unclear relevance are listed in the Supplementary Information for Table 1.
HLH, hemophagocytic lymphohistiocytosis; AR, autosomal recessive; eb, epidermolysis bullosa; X, X-linked; A, arthritis; vasc, vasculitis; n, nail; h, hair; AD, autosomal
dominant; e, eczema; f, folliculitis/pyoderma; SJ, Sjögren syndrome; p, psoriasis; AIHA, autoimmune hemolytic anemia; AN, autoimmune neutropenia; PSC, primary
sclerosing cholangitis; HT, Hashimoto thyroiditis; AIH, autoimmune hepatitis; TID, type 1 diabetes mellitus; MAS, macrophage activation syndrome; NSIP, non-speciﬁc
interstitial pneumonitis; S, serositis.
aPersonal information and communication.
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ulocytes. Patients typically present with high peripheral
granulocyte counts and bacterial infections, and some pre-
sent with IBD-like features.51,52
CD-like disease is a typical manifestation of glycogen
storage disease type Ib, characterized by neutropenia and
neutrophil granulocyte dysfunction.48,49,53 Granulocyte
colony-stimulating factor has been used to treat neutropenia
and colitis in some patients with glycogen storage disease
type Ib.53
In addition to neutrophil defects, defects in several other
genes, including WAS, LRBA, BTK, CD40LG, and FOXP3, can
lead to autoantibody-induced or hemophagocytosis-induced
neutropenia. These multidimensional mechanisms of sec-
ondary immune dysregulation indicate the functional
complexity of some seemingly unrelated genetic immune
defects and the broad effects they might have on the innate
immune system.
Hyperinﬂammatory and
Autoinﬂammatory Disorders
VEOIBD has been described in a number of hyper-
inﬂammatory and autoinﬂammatory disorders such as
mevalonate kinase deﬁciency,54,55 phospholipase C-g2 de-
fects,56 familial Mediterranean fever,57–59 Herman-
sky–Pudlak syndrome (type 1, 4, and 6),60–64 X-linked
lymphoproliferative syndrome type 165 and type 2,66–68 or
familial hemophagocytic lymphohistiocytosis type 5.69
Among these, mevalonate kinase deﬁciency is a prototypic
autoinﬂammatory disorder, characterized by increased
activation of caspase-1 and subsequent activation of IL-
1b.70 Inhibiting IL-1b signaling with antibodies that block
IL-1b or IL-1 receptor antagonists can induce complete or
partial remission in patients, including those with
VEOIBD.54,55,71
X-linked lymphoproliferative syndrome 2 is caused by
defects in the XIAP gene. At least 20% of patients with XIAP
defects develop a CD-like immunopathology with severe
ﬁstulizing perianal phenotype.66–68,72,73 In these patients,
Epstein–Barr virus infections can lead to life-threatening
hemophagocytic lymphohistiocytosis. Originally associated
with a poor outcome after HSCT,74 less toxic induction
regimens could improve the prognosis and cure this form of
IBD.67,73
Complex Defects in T- and B-Cell
Function
IBD-like immunopathology is a common ﬁnding in pa-
tients with defects in the adaptive immune system. Multiple
genetic defects that disturb T- and/or B-cell selection and
activation can cause complex immune dysfunction,
including immunodeﬁciency and autoimmunity as well as
intestinal inﬂammation. Disorders associated with IBD-like
immunopathology include B-cell defects such as common
variable immunodeﬁciency (CVID), hyper-immunoglobulin
(Ig) M syndrome, and agammaglobulinemia.75–79 Several
other primary immune deﬁciencies, such as Wiskott–Aldrich syndrome80 (WAS) and atypical SCID or Omenn
syndrome81,82 can also cause IBD-like intestinal
inﬂammation.CVID, Agammaglobulinemia, and Hyper
IgM Syndrome
Patients with CVID have clinical features of different
types of IBD, spanning CD, UC, and ulcerative proctitis–like
ﬁndings.83,84 Although CVID is largely polygenic, a small
proportion of cases of CVID have been associated with
speciﬁc genetic defects. CVID type 1 is caused by variants in
the gene encoding the inducible T-cell costimulator
(ICOS),85,86 whereas CVID type 8 is caused by variants in
LRBA.87–89 Patients with these mutations can present with
IBD-like pathology. Recently, IBD and CVID-like disease was
described in a family with IL-21 deﬁciency.90
Patients with agammaglobulinemia, caused by defects in
BTK or PIK3R1, as well as patients with subtypes of hyper
IgM syndrome caused by defects in CD40LG, AICDA, or
IKBKG can develop IBD-like immunopathology.75–79 It is
worth considering that several other immunodeﬁciencies,
not regarded as primary B-cell defects, are similarly asso-
ciated with low numbers of B cells and/or Igs (such as those
caused by variants in SKIV2L and TTC37; see Table 2 and
Supplementary Table 1).WAS
WAS is a primary immunodeﬁciency. Many patients with
WAS present with UC-like noninfectious colitis during early
infancy.80 The syndrome is caused by the absence or
abnormal expression of the cytoskeletal regulator WASP
and is associated with defects in most immune subsets
(effector and regulatory T cells, natural killer [NK] T cells, B
cells, dendritic cells, macrophages, NK cells, and neutro-
phils).91 In addition to features of UC, patients develop
many other autoimmune complications. Allogeneic bone
marrow transplantation is the standard of care for those
patients.80 Patients who are not candidates for bone
marrow transplantation have been successfully treated with
experimental gene therapy approaches.92,93Atypical SCID Defects
Patients with atypical SCID defects have residual B- and
T-cell development and oligoclonal T-cell expansion.94
VEOIBD is commonly observed in patients with atypical
SCID due to hypomorphic defects in multiple genes such as
DCLRE1C, ZAP70, RAG2, IL2RG, LIG4, ADA, and CD3G.81,82,95
This list of genes is likely not complete, and it seems
reasonable to assume that most genetic defects that cause T-
cell atypical SCID also cause IBD.
A subset of patients with SCID present with severe
eczematous rash (Omenn syndrome).81 It is not clear
whether residual lymphocyte function in patients with
hypomorphic TTC7A mutations is a precondition for IBD or
contributes to VEOIBD.38 Intestinal and skin lesions also
develop in patients with SCID due to graft-versus-host dis-
ease in response to maternal cells.96
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Hoyeraal–Hreidarsson syndrome is a severe form of
dyskeratosis congenita characterized by dysplastic nails,
lacy reticular skin pigmentation, and oral leukoplakia. It is
a multiorgan disorder. Patients with mutations in
RTEL197,98 or DKC199–101 can develop SCID and intestinal
inﬂammation.
Regulatory T Cells and IL-10 Signaling
Loss-of-function defects in IL-10 and its receptor
(encoded by IL10RA and IL10RB)102–106 cause VEOIBD with
perianal disease and folliculitis within the ﬁrst months of
life. All patients with loss-of-function mutations that prevent
IL-10 signaling develop IBD-like immunopathology, indi-
cating that these defects are a monogenic form of IBD with
100% penetrance.106,107 The anti-inﬂammatory cytokine IL-
10 is secreted by natural and induced regulatory T cells (in
particular, intestinal CD4þFOXP3þ and Tr1 cells), macro-
phages, and B cells. Many intestinal and extraintestinal cell
types express the IL-10 receptor and respond to IL-10.
Defects in IL-10 receptor signaling affect the differentia-
tion of macrophage M1/M2, shifting them toward an in-
ﬂammatory phenotype.108 Defects in IL-10 signaling are
associated with extraintestinal inﬂammation such as follic-
ulitis or arthritis and predispose to B-cell lym-
phoma.102,103,109 Conventional therapy options are largely
not effective in patients with IL-10 signaling defects, but
allogeneic matched or mismatched HSCT can induce sus-
tained remission of intestinal inﬂammation.30,102,103,107,110
X-linked immune dysregulation, polyendocrinopathy,
enteropathy syndrome (IPEX) is caused by mutations in the
transcription factor FOXP3. Those mutations affect natural
and induced regulatory T cells, causing autoimmunity and
immunodeﬁciency but also enteropathy in a large percent-
age of patients with colitis.111,112 The intestinal lesions that
develop in patients with IPEX can be classiﬁed as graft-
versus-host disease–like changes with small bowel
involvement and colitis, celiac disease–like lesions, or en-
teropathy with goblet cell depletion.113
Antibodies against enterocytes and/or antibodies
against goblet cells can be detected in the serum of patients
with IPEX.113 IPEX-like immune dysregulation with enter-
opathy can also be caused by defects in IL-2 signaling in
patients with defects in the IL-2 receptor a chain (IL2RA,
encoding CD25)114,115 or a dominant gain of function in
STAT1 signaling.116
Other Disorders and Genes
IBD or IBD-like disorders have been described in pa-
tients with several other disorders. In some disorders, there
is no well-deﬁned plausible functional mechanism. For
example, patients with trichohepatoenteric syndrome have
presumed defects in epithelial cells that lead to intractable
diarrhea.117,118 However, an adaptive immune defect might
also cause this disorder, because the patients have Ig de-
ﬁciencies that require Ig substitution.
Several genes, described in the Supplementary
Information for Table 1, are associated with a single orless well-deﬁned case report of patients who developed
IBD-like features. Some of these patients might happen to
have intestinal inﬂammation by coincidence, and even
several case reports cannot exclude a publication bias.
Heterozygous defects in the PTEN phosphatase are associ-
ated not only with multiple tumors but also immune dysregu-
lation and autoimmunity.119 Inﬂammatory polyps are common
among patients with PTEN hamartoma tumor syndrome and
indeterminate colitis, and ileitis is a rare complication.119 The
functional mechanism involved in intestinal inﬂammatory
polyps and intestinal inﬂammation is not clear because het-
erozygous mutations in PTEN are not associated with conven-
tional immunodeﬁciency and affect multiple cell types.
Very early onset enteropathies and intestinal infections
are described in several monogenic immunodeﬁciency and/
or autoinﬂammation disorders, including defects in the itchy
E3 ubiquitin protein ligase activity encoded by the ITCH
gene, defects in E3 ubiquitin ligase HOIL-1 encoded by
HOIL1, and gain of function defects in IKBA encoded by
NFKBIA (see Supplementary Information for Table 1). It is
not clear what activates the inﬂammatory events in those
patients; it could be pathogenic microbes in the intestine,
food, or IBD-like intestinal inﬂammation induced by the
commensal microbiota.
Additional disorders are associated with intestinal
inﬂammation without immunodeﬁciency or without known
epithelial mechanisms. For example, some patients with
Hirschsprung disease, an intestinal innervation and dys-
motility disorder, develop enterocolitis associated with
dominant germline mutations in RET.120,121 One possible
pathomechanism could be increased bacterial translocation
due to bacterial stasis leading to subsequent inﬂammation.
Despite multiple reports of complement system de-
ﬁciencies and IBD, this group of disorders is not clearly
deﬁned. MASP2 deﬁciency has been reported in a patient
with pediatric-onset IBD. However, reports of intestinal
inﬂammation in several other complement defects are much
harder to interpret because those patients present with
inconsistent disease phenotypes; some are less well docu-
mented and could be simple chance ﬁndings (see
Supplementary Information for Table 1).
Why Should We Care About
Monogenic Defects?
It is a challenge to diagnose the rare patients with
monogenic IBD, but differences in the prognosis and medi-
cal management argue that a genetic diagnosis should not
be missed. As a group, these diseases have high morbidity
and subgroups have high mortality if untreated. Based on
their causes, some require different treatment strategies
than most cases of IBD.
Allogeneic HSCT has been used to treat several mono-
genic disorders. It is the standard treatment for patients
with disorders that do not respond to conventional treat-
ment, those with high mortality, or those that increase
susceptibility to hematopoietic cancers (eg IL-10 signaling
defects, IPEX, WAS, or increasingly XIAP deﬁciency). Intro-
duction of HSCT as a potentially curative treatment option
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disorders has changed clinical practice.30,73,74,107,111
However, there is evidence from mouse models and
clinical studies that patients with epithelial barrier defects
are less amenable to HSCT, because this does not correct the
defect that causes the disease (eg, NEMO deﬁciency or
possibly TTC7A deﬁciency). For example, severe recurrence
of multiple intestinal atresia after HSCT in patients with
TTC7A deﬁciency36,37 indicates a contribution of the
enterocyte defect to pathogenesis. Due to the signiﬁcant risk
associated with HSCT, including graft-versus-host disease
and severe infections, it is important to determine the ge-
netic basis of each patient’s VEOIBD before selecting HSCT
as a treatment approach.
Understanding the pathophysiology of a disorder caused
by a genetic defect can identify unconventional biological
treatment options that interfere with speciﬁc pathogenic
pathways. Patients with mevalonate kinase deﬁciency or
CGD produce excess amounts of IL-1b, so treatment with
IL-1b receptor antagonists has been successful.54,55 This
treatment is not part of the standard therapeutic repertoire
for patients with conventional IBD. Access to individualized
genotype-speciﬁc therapies is particularly important,
because it might avoid both surgery (including colectomy)
and the adverse effects of medical therapy in patients who
are unlikely to beneﬁt from conventional IBD therapies in
the long term.
A further incentive to establish a speciﬁc genetic diag-
nosis is the ability to anticipate complications. Some pa-
tients should be screened for infections (such as for
Epstein–Barr virus infection status in XIAP defects) or can-
cer (including B-cell lymphomas in patients with IL-10 re-
ceptor deﬁciency109 or skin and hematopoietic malignancies
in Hoyeraal–Hreidarsson syndrome). Genetic information
can also identify patients who should be screened for
extraintestinal manifestations such as idiopathic thrombo-
cytopenic purpura, autoimmune hemolytic anemia, autoim-
mune neutropenia, or autoimmune hepatitis (Table 2).Table 3.Pivotal Prompts for Suspecting Monogenic IBD
Key points
Very early age of onset of IBD-like
immunopathology
Likelihood incre
of age at dia
Family history In particular con
family memb
Atypical endoscopic or histological ﬁndings For example, ex
Resistance to conventional therapies Such as exclus
Skin lesions, nail dystrophy, or hair abnormalities For example, ep
woolen hair,
Severe or very early onset perianal disease Fistulas and ab
Lymphoid organ abnormalities For example, ly
Recurrent or atypical infections Intestinal and n
Hemophagocytic lymphohistiocytosis Induced by vira
macrophage
Associated autoimmunity For example, ar
dysfunction
Early development of tumors For example, noKnowledge of the genetic predisposition can reduce the time
to detect associated complications.
Families who are aware of the genetic basis of their
disease can receive genetic counseling.When Should We Suspect
Monogenic IBD?
The timely diagnosis of monogenic IBD requires as-
sessments of intestinal and extraintestinal disease pheno-
types in conjunction with the histopathology and
appropriate laboratory tests to exclude allergies or in-
fections.18,19 Classiﬁcation of clinical, endoscopic, histologi-
cal, and imaging ﬁndings into CD-like and UC-like
phenotypes can be helpful but is not sufﬁcient to differen-
tiate patients with a monogenic disorder from conventional
idiopathic CD (such as discontinuous, transmural inﬂam-
mation affecting the entire gastrointestinal tract, ﬁstulizing
disease, or granuloma formation) or UC (a continuous,
colonic disorder with crypt abscess formation and increases
in chronic inﬂammatory cells, typically restricted to the
lamina propria). Histopathologists use nonspeciﬁc terms
such as IBD unclassiﬁed in a relevant proportion of patients
with VEOIBD, including monogenic forms of IBD. In the
absence of highly speciﬁc and sensitive intestinal histologi-
cal markers of monogenic forms of IBD, extraintestinal
ﬁndings and laboratory test results are important factors to
focus the search for monogenic forms of IBD (Table 3 and
Figure 2). A phenotypic aide-mémoire summarizing the key
ﬁndings to ensure that a careful clinical history for VEOIBD
and examination to narrow the search for an underlying
monogenetic defect is YOUNG AGE MATTERS MOST (YOUNG
AGE onset, Multiple family members and consanguinity,
Autoimmunity, Thriving failure, Treatment with conven-
tional medication fails, Endocrine concerns, Recurrent in-
fections or unexplained fever, Severe perianal disease,
Macrophage activation syndrome and hemophagocytic
lymphohistiocytosis, Obstruction and atresia of intestine,Comments
ases with very early onset, particularly in those younger than 2 years
gnosis
sanguinity, predominance of affected males in families, or multiple
ers affected
treme epithelial apoptosis or loss of germinal centers
ive enteral nutrition, corticosteroids, and/or biological therapy
idermolysis bullosa, eczema, folliculitis, pyoderma or abscesses,
or trichorrhexis nodosa
scesses
mph node abscesses, splenomegaly
onintestinal
l infections such as Epstein–Barr virus or cytomegalovirus or
activation syndrome
thritis, serositis, sclerosing cholangitis, anemia, and endocrine
such as thyroiditis, type 1 diabetes mellitus
n-Hodgkin lymphoma, skin tumors, hamartoma, thyroid tumors
Figure 2. Diagnosis of VEOIBD. Patient and family history, physical examination, endoscopic investigations, imaging, and
limited biochemistry and microbiology/virology tests are required to establish the diagnosis of IBD, assess disease localization
and behavior, and determine inﬂammatory activity. If there is doubt, those tests can contribute to exclude the much more
frequent gastrointestinal infections and non-IBD immune responses toward dietary antigens. Cow’s milk protein allergy can
present with enteropathy and colitis, and celiac disease can mimic autoimmune enteropathies. Fecal calprotectin can be
helpful but may be increased even in healthy infants. The current diagnostic strategy to investigate a monogenic cause of IBD-
like intestinal inﬂammation is largely based on restricted functional screening followed by genetic conﬁrmation. A restricted set
of laboratory tests is needed to propose candidate genes of the most common genetic defects for subsequent limited
sequencing. As a complementary approach, genetic screening for IBD-causative rare variants using next-generation
sequencing might be followed by limited functional conﬁrmatory studies. The complexity of problems in these children re-
quires interdisciplinary support, including pediatric gastroenterologists, immunologists, geneticists, and infectious disease
specialists. CBC, complete blood count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; CMV, cytomegalo-
virus; TB, tuberculosis; HIV, human immunodeﬁciency virus; CMPA, cow’s milk protein allergy.
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ESSkin lesions and dental and hair abnormalities, and Tu-
mors). An important component of management is to solicit
advice from a specialist in VEOIBD.
Very early age of onset of intestinal symptoms and IBD-
like endoscopic and histological changes are strong in-
dicators of monogenic IBD as a group (Figure 1). However,
there are clear gene-speciﬁc differences in the age of onset.
The reported time of onset of IBD-like immunopathology in
subgroups with, for example, IL-10 signaling defects, WAS, or
IPEX, is infancy and early childhood. However, atypical late
onset of IBD has been reported in patients withWAS122,123 as
well as IPEX.124–126 The age is variable in neutrophil defects,
B-cell defects, and XIAP deﬁciency. Indeed, XIAP deﬁciency
caused by identical genetic defects within families can be
associated with VEOIBD or adult-onset IBD.68,73,127 Other
diseases, such as GUCY2C deﬁciency, typically develop during
adulthood (Figure 1). Phenotypes of many monogenic forms
of IBD change over time; gastrointestinal problems can pre-
sent as an initial or a later ﬁnding.
Some candidate disorders will be recognized by their
pathognomonic symptom combinations. Because there are
no speciﬁc and fully reliable endoscopic and histological
features of monogenic VEOIBD, patients with VEOIBD and
multiple other features (listed in Table 3) should beconsidered to have increased likelihood to carry disease-
causing mutations. The degree of suspicion should dictate
the extent of functional and genetic exploration for an un-
derlying cause. It is important to emphasize that in the ma-
jority of patients with infantile IBD or VEOIBD, no genetic
defect has currently been discovered that would explain the
immunopathology. This fraction of causative defects will in-
crease as our knowledge expands and with a growing num-
ber of patients undergoing whole-exome sequencing (WES).
Although young age of IBD onset is a strong indicator, a
strong suspicion for amonogenic cause should lead to limited
functional or genetics screening irrespective of age.
Laboratory Tests and Functional
Screens
Laboratory tests, upper and lower gastrointestinal
endoscopy with histological analysis of multiple biopsy
specimens, and imaging should be performed for every
patient with VEOIBD according to guidelines.13,18–21,128
Histological investigation is paramount not only to differ-
entiate IBD-like features but also to exclude other estab-
lished pathologies such as eosinophilic or allergic
gastrointestinal disease and infection.
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vere colitis that resembles UC and even requires hospitali-
zation. It manifests typically within the ﬁrst 2 to 3 months of
exposure to cow’s milk protein. This may be apparent with
breast-feeding or only after introducing formula feeding.
Colitis resolves after cow’smilk is removed from the diet, so a
trial of exclusive feeding with an amino acid–based infant
formula is a customary treatment strategy for all VEOIBD
diagnosed when the patient is younger than 1 year of age.
However, improvement of symptoms or inﬂammation does
not exclude the possibility that a patient could have a
monogenetic IBD disorder, because food intolerance and al-
lergy can be secondary to the disorder and allergen avoid-
ance by exclusive enteral nutrition with elemental formula
could also alleviate the inﬂammation of classic IBD.
High levels of IgE and/or eosinophilia are also found in
patients with monogenic disorders caused by defects in
FOXP3, IL2RA, IKBKG, WAS, or DOCK8 (Table 2 and
Supplementary Table 1). It should also be standard practice
to exclude infectious causes such as bacteria (Yersinia spp,
Salmonella spp, Shigella spp, Campylobacter spp, Mycobac-
terium tuberculosis, Clostridium difﬁcile), parasites
(Entamoeba histolytica, Giardia lamblia), and viral infections
(cytomegalovirus or human immunodeﬁciency virus),
remembering that some infections can mimic IBD. However,
most of these pathogens do not cause bloody diarrhea for
more than 2 to 3 weeks. In addition, monogenic disorders
(such as B- or T-cell defect immunodeﬁciencies or familial
HLH type 5, caused by STXBP2 deﬁciency) predispose pa-
tients to intestinal infections.69 Celiac disease should be
considered as a differential diagnosis for patients with
suspected autoimmune enteropathy presenting with villous
atrophy (such as IPEX or IPEX-like patients).
To detect possible causes of monogenic IBD-like immu-
nopathology, we propose additional laboratory screening
for all children diagnosed before 6 years of age. The limited
set of laboratory tests includes measurements of IgA, IgE,
IgG, and IgM; ﬂow cytometry analysis of lymphocyte subsets
(CD3, CD4, CD8, CD19/CD20, NK cells); and analysis of
oxidative burst by neutrophils (using the nitro blue tetra-
zolium test or ﬂow cytometry–based assays such as the
dihydrorhodamine ﬂuorescence assay).
When placed in the context of clinical, histopathologic,
and radiological data, these tests can guide the diagnosis
toward the more prevalent defects of neutrophil, B-cell, or
T-cell dysfunction. Further tests are necessary to charac-
terize particular subgroups, such as those who develop the
disease when they are younger than 2 years of age, those
with excessive autoimmunity, or those with severe perianal
disease. Those tests include ﬂow cytometry analysis of XIAP
expression by lymphocytes and NK cells129,130 or FOXP3
expression in CD4þ T cells, which can diagnose a signiﬁcant
proportion of patients with XLP2 and IPEX. Flow cytometry
can detect functional defects in MDP signaling in patients
with XIAP deﬁciency.131 IL10RA and IL10RB defects can be
detected by assays that determine whether exogenous IL-10
will suppress lipopolysaccharide-induced peripheral blood
mononuclear cell cytokine secretion or IL-10–induced
STAT3 phosphorylation.30,103,107 Increased levels ofantibodies against enterocytes can indicate autoimmune
enteropathy, in particular in patients with IPEX.
In contrast to measurements of Igs, ﬂow cytometry, and
oxidative burst assays (which are largely standardized),
other tests such as IL-10–mediated suppression of LPS-
induced peripheral blood mononuclear cell activation and
detection of antibodies against enterocytes are nonroutine
assays. Similarly, additional tests for extremely rare genetic
defects might be appropriate but are only available at
specialized laboratories, often as part of research projects.
The clinical utility of the algorithm to use a limited set of
laboratory tests to differentiate between conventional and
monogenic VEOIBD, as suggested in Figure 2, is based on
experience, case reports, and case series of individual dis-
orders. It has not been validated in prospective studies of
patients with all forms of VEOIBD.Diagnosis via Sequencing of Candidate Genes
Versus Parallel Next-Generation Sequencing
The classic approach to detect monogenic forms of IBD,
as described in the preceding text and summarized in
Figure 2, is based on careful phenotypic analysis and
candidate sequencing to conﬁrm a suspected genetic diag-
nosis. Due to the increasing number of candidate genes,
sequential candidate sequencing can be costly and time
consuming. It is therefore not surprising to propose that this
strategy of functional screening followed by genetic conﬁr-
mation will increasingly be complemented by early parallel
genetic screening using next-generation sequencing fol-
lowed by functional conﬁrmation. The US Food and Drug
Administration has recently granted marketing authoriza-
tion for the ﬁrst next-generation genomic sequencer, which
will further pave the way for genome, exome, or other tar-
geted parallel genetic tests in routine practice.132,133 WES or
even whole-genome sequencing will increasingly become
part of the routine analysis of patients with suspected ge-
netic disorders including subtypes of IBD.59,134,135 This has
several important implications for selecting candidate gene
lists, identiﬁcation of disease-causing variants, and dealing
with a large number of genetic variants of unknown rele-
vance. In research and clinical settings, WES has been
shown to reliably detect genetic variants that cause VEOIBD
in genes such as XIAP,67 IL10RA,136,137 G6PC3,138 MEFV,59
LRBA,88 FOXP3,126 and TTC7A.38
There are several reasons to propose extended parallel
candidate sequencing for patients with suspected mono-
genic IBD. Immune and gastrointestinal phenotypes of pa-
tients evolve over time, whereas the diagnosis needs to be
made at the initial presentation to avoid unnecessary tests
and treatment. IBD-like immunopathology can be linked to
nonclassic phenotypes of known immunodeﬁciencies, such
as hypomorphic genetic defects in SCID patients (in genes
such as ZAP70, RAG2, IL2RG, LIG4, ADA, DCLRE1C, CD3G, or
TTC7A; see Table 2) with residual B- and T-cell develop-
ment,38,81,82 glucose-6-phosphatase 3 deﬁciency with lym-
phopenia,50 or FOXP3 defects without the classic IPEX
phenotype.126 WES has revealed unexpected known causa-
tive variants67 even after workup in centers with specialized
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all demonstrates that current knowledge about the disease
phenotype spectrum is incomplete, which means that a pure
candidate approach is not reliable and genetic screening
may have advantages. The 50 monogenic defects associated
with IBD provide an initial ﬁlter to identify patients with
monogenic disorders.
Because of the greatly reduced costs of next-generation
sequencing, it is probably cost effective in many cases to
perform multiplex gene sequencing, WES, or whole-genome
sequencing rather than sequential Sanger sequencing of
multiple genes. A big advantage of WES is the potential to
identify novel causal genetic variants once the initial
candidate ﬁlter list of known disease-causing candidates has
been analyzed. The number of gene variants associated with
VEOIBD is indeed constantly increasing, largely due to the
new sequencing technologies, so data sets derived from
WES allow updated analysis of candidates as well as novel
genes. Because multiple genetic defects can lead to spon-
taneous or induced colitis in mice,1,139 assuming homology,
it is likely that many additional human gene variants will be
associated with IBD.
Targeted sequencing of genes of interest is an alternative
approach to exome-targeted sequencing. Initial studies to
perform targeted next-generation parallel sequencing
showed the potential power of this approach.140 Targeted
next-generation sequencing of the 170 primary immuno-
deﬁciency (PID)-related genes accurately detected point
mutations and exonic deletions.140 Only 9 of 170 PID-
related genes analyzed showed inadequate coverage. Four
of 26 patients with PID without an established prescreening
genetic diagnosis, despite routine functional and genetic
testing, were diagnosed, indicating the advantage of parallel
genetic screening. Because a major group of VEOIBD-
causing variants is associated with PID-related genes, it is
obvious how this approach can be adapted and extended to
monogenic IBD genes.
Genetic approaches also offer practical advantages.
Specialized functional immune assays are often only avail-
able in research laboratories and are not necessarily vali-
dated; functional tests often require rapid processing of
peripheral blood mononuclear cells or biopsy specimens in
specialized laboratories. This means that handling of DNA
and sequencing seems far less prone to error or variation.
However, relying solely on genetic screening can be
misleading, because computational mutation prediction can
fail to detect functional damaging variants. For example,
variants in the protein-coding region of the IL10RA genewere
misclassiﬁed as “tolerated” by certain prediction tools,
whereas other prediction tools and functional analysis re-
ported defects in IL-10 signaling.30 Although most studies
report variants in protein-coding regions in monogenic dis-
eases, there could be selection bias. It is indeed far more
difﬁcult to establish thebiological effects of variants that affect
processes such as splicing, gene expression, or messenger
RNA stability. It should go without saying that novel genetic
variants require appropriate functional validation.
The increased availability of sequencing data sets high-
lights the role of mutation-speciﬁc IBD-causing variants thatillustrate the functional balance of gene products affected by
gain or loss of function variants as well as gene dosage ef-
fects. Inherited gain-of-function mutations in guanylyl
cyclase cause diarrhea and increase susceptibility to IBD,
whereas loss-of-function mutations lead to intestinal
obstruction and meconium ileus.141 Gain-of-function muta-
tions in STAT1 cause an IPEX-like syndrome with enterop-
athy,116 whereas loss-of-function mutations are found in
patients with autosomal dominant chronic mucocutaneous
candidiasis.142 Loss of TTC7A activity results in multiple
intestinal atresia and SCID,36,37,143 whereas hypomorphic
mutations cause VEOIBD.38 Similarly, loss-of-function vari-
ants cause classic SCID defects, whereas hypomorphic
variants in the same genes allow residual oligoclonal
T-cell activation and are associated with immunopathology,
including colitis.
Performing next-generation sequencing exome-wide or
genome-wide will identify (in each patient) genetic variants
of unknown relevance and, in some patients, known vari-
ants that are associated with incomplete penetrance or
variable phenotype severity. Increasing use of DNA
sequencing technologies will lead to detection of hypo-
morphic variants that cause milder phenotypes and/or later
onset of IBD. The increased availability of genotype-
phenotype data sets in databases such as ClinVar (http://
www.ncbi.nlm.nih.gov/clinvar)144 or commercial databases
will increase our ability to differentiate variants that cause
IBD from those without biological effects. WES analysis of
patients with pediatric onset of IBD, including VEOIBD, has
revealed multiple rare genetic variants in those IBD sus-
ceptibility genes that were discovered by association
studies.145 Similarly, WES analysis of patients with geneti-
cally conﬁrmed mevalonate kinase deﬁciency identiﬁed
multiple variants in IBD-related genes outside of the MVK
gene.146 It is currently not clear how strongly these rare
variants inﬂuence the genetic susceptibility to IBD as addi-
tive or synergistic factors. In particular, in patients with
nonconventional forms of IBD, the identiﬁcation of variants
of unknown relevance can lead to the therapeutic dilemma
of whether to wait for the disease to progress or start early
treatment. Because some of the disease-speciﬁc treatment
options have potentially severe adverse effects, careful
evaluation of genetic variants is required not only to vali-
date sequence data147 and statistical association but to
provide functional evidence that those variants cause
disease.133,148Conclusion
Rare monogenic disorders that affect intestinal immune
and epithelial function can lead to VEOIBD and severe
phenotypes. These disorders are diagnosed based on clin-
ical and genetic information. Accurate genetic diagnosis is
required for assessing prognosis and proper treatment of
patients. We summarized phenotypes and laboratory ﬁnd-
ings for more than 50 monogenic disorders and suggest a
diagnostic strategy to identify these extremely rare dis-
eases, which have large effects on patients and their
families.
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Supplementary Information for Table 1
Examples of genetic variants with potential association
with IBD and syndromes associated with IBD are shown. A
systematic review of the literature was performed, focusing
on IBD-like immunopathology in monogenic disorders
largely through PubMed and OMIM databases. In addition to
an iterated literature search focused on pediatric onset or
monogenic IBD, an extensive list of primary immunodeﬁ-
ciencies1,2 was searched for occurrence of the PID-
associated gene symbols (partially gene or protein name)
with reports of “colitis” or “Crohn” or “IBD” or “inﬂamma-
tory bowel disease.” A list of likely causative gene defects
with association with IBD-like immunopathology was
created. We selected intestinal and extraintestinal clinical
features as well as laboratory ﬁndings that deﬁne key sub-
groups of patients with prototypic monogenic defects.
For each genetic defect, relevant reports were retrieved
and selected clinical features and laboratory parameters
were recorded. Data extraction was performed indepen-
dently by 4 clinicians using a structured approach. Dis-
agreements in data interpretation were resolved by several
rounds of discussion until consensus was reached. All au-
thors discussed key phenotype criteria that suggest mono-
genic IBD-like immunopathology as well as the core
diagnostic approach to VEOIBD.
Because there are a number of hypomorphic variants
with nonconventional phenotype, the key ﬁndings were
extracted from the patients with IBD-like immunopathology
and are therefore often but not necessarily representative of
the classic disease phenotype. Activation mutations (gain of
function) in IKBA are associated with diarrhea due to en-
teropathy, early intestinal infections, and possibly colitis.3–6
ITCH deﬁciency can lead to autoimmune enteropathy with
lymphocytic inﬂammation of the small bowel lamina prop-
ria, associated with antienterocyte antibodies, perinuclear
antineutrophil cytoplasmic antibodies, or anti–smooth
muscle antibodies.7
A very early onset of colitis was reported in a girl with
severe congenital hypertriglyceridemia. WES identiﬁed
compound heterozygous mutations in the GPIHBP1 gene.8
Patients who developed IBD have been reported in other
disorders. These include SIRT1 defects,9 Wolfram syndrome
(WFS1),10 Niemann–Pick type C disease (NPC1),11–13 Char-
cot–Marie–Tooth disease (CMT4C),14 Gorlin syndrome
(PTCH1),15 and Brooke–Spiegler syndrome (CYLD).16
No genetic diagnosis was provided in a patient with Che-
diak–Higashi syndrome17 and patients with autoimmune
lymphoproliferative syndrome18 (personal communication,
David Teachey, October 2013). Clear syndromal features
without genetic diagnosis are seen in other patients, such as in
pigmentary disorder, reticulate, with systemic manifestation
(PDR syndrome)19 or leukoencephalopathy, arthritis, colitis,
and hypogammaglobulinemia (LACH syndrome).20 Inﬂam-
mation of the small and large bowel was found in patients
with tufting enteropathy conﬁrmed by negative epithelial cell
adhesion molecule immunohistochemical staining.21 Inter-
estingly, the inﬂammatory inﬁltrates in those patients with
tufting enteropathy resolved spontaneously over time.
A group of complement defects can present with intes-
tinal inﬂammation. Despite a range of possible candidate
genes, for the majority there is either no genetic diagnosis
provided, no histological proof of IBD-like intestinal
inﬂammation, or single patient adult-onset IBD that could
present a chance ﬁnding or publication bias (reviewed by
Marks et al22,23). This includes C2 deﬁciency and C1-
esterase deﬁciency (reviewed by Marks et al22,23), C6 deﬁ-
ciency,24 or H-ﬁcolin deﬁciency (FCN3).25
Supplementary Information for Figure 1
Additional information is provided regarding age of in-
testinal inﬂammation in patients with CGD,26,27 IPEX,28–47
WAS,48–51 ITGB2,52 IL10RA,53 and LRBA defects.
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